You are here: Industry Insights > Victoza

News List

Novo Nordisk's oral semaglutide impresses analysts against Victoza, Januvia fiercepharma
June 25, 2018
Once it wins approval, Novo Nordisk’s highly anticipated oral diabetes drug semaglutide will go up against some stiff competition. But the drugmaker just showed that its up-and-comer can take the heat.
Novo's oral semaglutide beats Victoza and Januvia in diabetes pharmafile
June 22, 2018
Novo Nordisk has released new data for its oral semaglutide diabetes therapy from two trials, showing that the GLP-1 analogue was more effective in reducing HbA1c and weight in patients compared to MSD’s Januvia (sitagliptin) and its own best-selling inje
Novo petitions FDA to require Victoza copies to go through clinical trials, pointing to complex manu fiercepharma
October 10, 2017
With one drugmaker already trying to pry patent protection off of Novo Nordisk’s blockbuster Victoza before its 2022 expiration, the insulin specialist has taken new steps to deter copies.
Victoza reduces the risk of major cardiovascular events in type 2 diabetes patients biospectrumasia
August 30, 2017
This post-hoc analysis was presented at the European Society of Cardiology (ESC) Annual Congress in Barcelona, Spain.
Victoza indicated to reduce the risk of three major adverse cardiovascular events biospectrumasia
August 28, 2017
The U.S. Food and Drug Administration (FDA) has approved a new indication for Victoza (liraglutide) to reduce the risk of major adverse cardiovascular (CV) events, heart attack, stroke and CV death, in adults with type 2 diabetes and established CV diseas
Victoza Receives Positive Vote from FDA Advisory Committee americanpharmaceuticalreview
June 22, 2017
Novo Nordisk announced the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) has completed its meeting regarding the supplemental New Drug Application (sNDA) for ...

Previous page 1 2 Next page